Analyst Jason Gerberry of Bank of America Securities reiterated a Hold rating on Pfizer, with a price target of $28.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jason Gerberry has given his Hold rating due to a combination of factors including the absence of significant catalysts for Pfizer’s stock and the company’s ongoing challenges with its multi-year loss of exclusivity period, which is expected to last until 2029. Despite these challenges, Pfizer’s stock is supported by its low sector multiple and an attractive dividend yield, which provides some balance.
Looking forward to 2026, Gerberry anticipates that Pfizer’s growth will be relatively flat, driven by tight expense management and a lack of major new product launches. The company’s revenue is expected to decline slightly due to a few small losses of exclusivity and negotiations around Eliquis, although this may be partially offset by growth in certain brands. Additionally, the year is expected to be light in terms of impactful pipeline data, with a focus on obesity drug developments and other ongoing projects.
According to TipRanks, Gerberry is a 5-star analyst with an average return of 14.7% and a 60.08% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Jazz Pharmaceuticals, and Arcellx Inc.
In another report released on December 12, Morgan Stanley also maintained a Hold rating on the stock with a $28.00 price target.